Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019

Table 1 Susceptibility of lower respiratory tract infection isolates of P. aeruginosa and Enterobacterales to C/T and comparator agents^a,b – SMART 2018–2019, United States

Species	n	% Susceptible
Species	n	C/T	P/T	FEP	CAZ	CRO	ATM	MEM	IMI	LVX	AMK
P. aeruginosa	1237	96.0	74.4	79.2	78.5	NA	68.2	74.8	65.2	63.1	96.0
All Enterobacterales^c	1938	91.8	88.0	89.5	83.4	80.1	84.2	98.0	86.4	82.2	98.8
K. pneumoniae	432	92.6	86.8	82.2	79.9	80.3	81.9	96.5	95.1	81.0	98.4
E. coli	359	97.2	91.9	84.7	82.2	79.4	82.5	99.7	99.7	66.6	98.9
S. marcescens	261	95.8	93.5	96.6	95.8	84.3	93.5	96.9	84.3	90.8	97.3
E. cloacae	176	77.8	79.0	89.8	72.2	69.3	73.9	98.9	94.3	94.3	100
K. aerogenes	152	79.6	73.0	94.1	70.4	67.8	72.4	98.0	73.0	93.4	100
K. oxytoca	138	97.8	87.7	94.9	96.4	87.0	91.3	97.8	97.1	99.3	100
P. mirabilis	121	99.2	100	95.0	96.7	95.9	97.5	100	19.8	61.2	99.2
P. aeruginosa + Enterobacterales	3175	93.5	82.7	85.5	81.5	NA	78.0	88.9	78.2	74.8	97.7

^a Abbreviations: C/T, ceftolozane/tazobactam; P/T, piperacillin/tazobactam; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ATM, aztreonam; MEM, meropenem; IMI, impenem; LVX, levofloxacin; AMK, amikacin, NA, not available
^b Table does not show results for colistin because P. aeruginosa and Enterobacterales cannot be categorized as susceptible to colistin using CLSI M100 (2020) MIC breakpoint criteria
^c Table only shows data for individual species of Enterobacterales when n > 100

ISSN: 1471-2180